Quest Diagnostics Incorporated
DGXHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeQuest Diagnostics Incorporated provides diagnostic testing and services in the United States. With a market capitalization of $26.70B, it sits in large-cap territory. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Market Cap
$26.70B
Beta
0.54
P/E (TTM)
25.68
P/E (Fwd)
20.10
EPS (TTM)
$9.42
EPS (Fwd)
$12.03
ROE
15.3%
ROA
6.6%
Cash
$797.0M
Total Debt
$6.40B
Free CF
$872.5M
52W Change
34.2%
Annual Financials
Cash vs Debt
Where DGX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DGX finished 10.27% above its 150-day moving average ($213.04) and 13.13% above its 200-day moving average ($207.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DGX overbought or oversold?
At the October 20, 2026 close, DGX's RSI(14) was 56.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, DGX has $797.0M in cash with $6.40B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $872.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 15.3%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $9.88B to $11.04B.
The relatively low beta of 0.54 suggests DGX is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Quest Diagnostics Incorporated and its sector.